Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In postmenopausal osteoporosis, there is an increased risk of spontaneous vertebral fractures (VFs) of about 1 to 10%, rarely described in women under denosumab for aromatase inhibitors (AI)-treated breast cancer.
|
31598815 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
|
31847542 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
|
31606823 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
|
31678641 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies targeting the androgen receptor (AR) signaling pathway in aromatase inhibitor (AI)-resistant breast cancer are limited.Bicalutamide, one of the commonly used AR inhibitors in prostate cancer, in combination with AI, did not show synergistic activity in patients with estrogen receptor-positive and AI-resistant disease in this phase II, single-arm study.The clinical benefit rate and objective response rate at 6 months were 16.7% and 0%, respectively, and the study was terminated after the first stage.
|
31434793 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In spite of the significant progress of estrogen-dependent breast cancer (BC) treatment, aromatase inhibitor resistance is a major problem limiting the clinical benefit of this frontier endocrine-therapy.
|
31610224 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hs578t cells expressed aromatase (CYP19) mainly via the healthy stromal CYP19 promoter I.4, but also to a lesser extent via the breast cancer-relevant promoters PII, I.3 and I.7, and produced estrogens from androgen precursors.
|
31629071 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functional studies in breast cancer have shown associations between MMR loss, resistance to aromatase inhibitors and sensitivity to palbociclib (Haricharan et al. in Cancer Discov 7:1168-1183, 2017).
|
31522348 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aromatase is an attractive target for the diagnosis and treatment of breast cancer.
|
31816749 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer.
|
31609762 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our analysis points to an impact of UGT2B17 and CYP19A1 in postmenopausal endocrine responsive breast cancer.
|
30967597 |
2020 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These compounds were evaluated for inhibition of aromatase enzyme of breast cancer in assistance by molecular docking simulations to understand molecular interaction between the enzyme and ligands.
|
31584741 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]).
|
31839281 |
2020 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were stratified according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk.
|
31596961 |
2020 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Women with breast cancer treated with aromatase inhibitor (AI) therapy experience multiple concurrent symptoms or symptom clusters.
|
31610271 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
She underwent right mastectomy for breast cancer and had received aromatase inhibitor and denosumab therapy for 5 years.
|
31527321 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tamoxifen and aromatase inhibitors have been the mainstay of endocrine therapy and have improved breast cancer survival.
|
31630379 |
2019 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
|
31321612 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC.
|
30561133 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
OET, including tamoxifen and aromatase inhibitors, is considered standard adjuvant therapy for HR+ breast cancer.
|
30523459 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
This manuscript aims at providing an updated overview on the role of adding ovarian function suppression to tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy in premenopausal women with estrogen receptor-positive early breast cancer.
|
30299291 |
2019 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tamoxifen, raloxifene, and the aromatase inhibitors exemestane and anastrozole reduce invasive breast cancer in women without preexisting breast cancer, but also cause adverse effects that vary by medication.
|
31509915 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
A supervised analysis of microarray data from the Alliance/ACOSOG Z1031 neoadjuvant aromatase inhibitor (AI) trial identified upregulated genes in Luminal B breast cancers that correlated with AI-resistant tumor proliferation (Pearson's correlation r ≥ 0.4 with Ki67) (33 cases Ki67 >10% on AI) versus Luminal-B breast cancers that were more AI-sensitive (33 cases Ki67 <10% on AI).
|
31665365 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aromatase inhibitors (AI) used in breast cancer induce loss in bone mineral density (BMD) and are reported to increase fracture risk.
|
31069862 |
2019 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ovarian function suppression (OFS) with tamoxifen or aromatase inhibitors (AIs) improves disease-free survival in premenopausal women with breast cancer, mostly in those at higher risk of recurrence.
|
31327728 |
2019 |